Licensing Agreement
Innovent Enters a Licensing Agreement with Lilly to Develop & Commercialize a Novel Diabetes Medicine in China
Innovent
PR-M08-19-NI-076Aug 27, 2019
Oncology
Innovent Announces First Patient Dosed in a Phase III Clinical Trial of Anti-PD-1 Antibody Tyvyt® (Sintilimab injection) as First-line Treatment for Patients with Advanced Esophageal Cancer
Innovent Biologics, Inc.
PR-M01-19-NI-012Jan 08, 2019
Innovent Announces First Patient Dosed in a Phase III Clinical Trial of Anti-PD-1 Antibody Tyvyt®
Innovent
PA3190Jan 07, 2019